HRS-9531
- Generic Name
- HRS-9531
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 540
- Registration Number
- NCT06396429
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06391710
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
HRS9531 Controls Weight Regain in Obese Subjects
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06287437
- Locations
- 🇨🇳
Xiaoying Li, Shanghai, China
A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06246175
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects
- Conditions
- Overweight or Obesity
- Interventions
- Drug: HRS9531 injection Placebo
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06054698
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HRS9531 injection Placebo
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 199
- Registration Number
- NCT05966272
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
A Relative Bioavailability Study of HRS9531 in Healthy Subjects
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05893576
- Locations
- 🇨🇳
Central hospital affiliated to Shandong first mecical university, Jinan, Shandong, China
Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
- Conditions
- Overweight or Obesity
- Interventions
- Drug: HRS9531 injection Placebo
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 249
- Registration Number
- NCT05881837
- Locations
- 🇨🇳
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳The people's hospital of Longhua.Shenzhen, Shenzhen, Guangdong, China
🇨🇳The First People's Hospital Of Lianyungang, Lianyungang, Jiangsu, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT05516966
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05152277
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.